[go: up one dir, main page]

UY27296A1 - Composición farmacéutica que contiene mosaprida y pancreatina - Google Patents

Composición farmacéutica que contiene mosaprida y pancreatina

Info

Publication number
UY27296A1
UY27296A1 UY27296A UY27296A UY27296A1 UY 27296 A1 UY27296 A1 UY 27296A1 UY 27296 A UY27296 A UY 27296A UY 27296 A UY27296 A UY 27296A UY 27296 A1 UY27296 A1 UY 27296A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
pancreatin
composition containing
containing mosapride
mosapride
Prior art date
Application number
UY27296A
Other languages
English (en)
Inventor
Joaquina Faour
Juan Antonio Vergez
Marcelo A Ricci
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of UY27296A1 publication Critical patent/UY27296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica que contiene mosaprida, pancreatina y opcionalmente simeticona y es utilizada para el tratamiento, prevención o alivio de los síntomas de un desorden gastrointestinal. La composición farmacéutica es provista en una forma de dosificación oral para la administración a un sujeto.
UY27296A 2001-05-23 2002-05-20 Composición farmacéutica que contiene mosaprida y pancreatina UY27296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/864,767 US6676933B2 (en) 2001-05-23 2001-05-23 Pharmaceutical composition containing mosapride and pancreatin

Publications (1)

Publication Number Publication Date
UY27296A1 true UY27296A1 (es) 2003-04-30

Family

ID=25344028

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27296A UY27296A1 (es) 2001-05-23 2002-05-20 Composición farmacéutica que contiene mosaprida y pancreatina

Country Status (3)

Country Link
US (1) US6676933B2 (es)
AR (1) AR034231A1 (es)
UY (1) UY27296A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434388C (en) * 2001-01-12 2012-08-21 Innovation Ventures, Llc Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
WO2004066913A2 (en) * 2003-01-31 2004-08-12 Takeda Pharmaceutical Company Limited Solid mosapride preparation
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
WO2006011638A1 (ja) * 2004-07-28 2006-02-02 Dainippon Sumitomo Pharma Co., Ltd. 複数の被覆層を有するフィルムコーティング錠
KR101045508B1 (ko) * 2004-07-28 2011-06-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 필름 코팅정
US7153504B2 (en) * 2004-07-30 2006-12-26 Can Technologies, Inc. Stabilized pancreas product
MX2008000850A (es) 2005-07-29 2008-03-18 Solvay Pharm Gmbh Procedimientos para la fabricacion de polvo de pancreatina esterilizada.
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070077836A1 (en) * 2005-09-30 2007-04-05 General Electric Company Methods and apparatus for stabilizing exposed fabric edge
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
JP2009516637A (ja) * 2005-11-04 2009-04-23 味の素株式会社 消化管機能亢進剤
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2078052B1 (en) * 2006-10-31 2010-07-28 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
WO2008131259A1 (en) * 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
ITMI20120131A1 (it) * 2012-02-01 2013-08-02 Probiotical Spa Batteri probiotici microincapsulati multistrato, loro produzione ed uso
EP3162371A1 (en) * 2015-10-27 2017-05-03 Przemyslaw Taciak A composition comprising simethicone, gastric acid-neutralizing substances and gastric enzyme(s) (e.g. pancreatine) for use in the treatment of digestive disorders
MA46207A (fr) 2016-09-09 2019-07-17 Int Agriculture Group Llc Alternative au cacao naturel et ses procédés de production
WO2018049242A1 (en) 2016-09-09 2018-03-15 International Agriculture Group, LLC Yogurt product from high starch fruits
MX390102B (es) * 2017-02-07 2025-03-20 Rhein Siegfried Sa De Cv Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla.
JP7282753B2 (ja) * 2017-09-29 2023-05-29 ジョンソン アンド ジョンソン コンシューマー インコーポレイテッド 固体シメチコン粒子及びその剤形
CN110721151B (zh) * 2019-11-29 2023-09-12 远大生命科学(武汉)有限公司 一种西甲硅油复方液体组合物及其制备方法和应用
CN114591260B (zh) * 2020-12-05 2025-07-11 鲁南制药集团股份有限公司 一种莫沙必利有机酸盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations

Also Published As

Publication number Publication date
AR034231A1 (es) 2004-02-04
US20030007962A1 (en) 2003-01-09
US6676933B2 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
ES2091173T3 (es) Nueva composicion farmaceutica que contiene el inhibidor de la ace ramipril y un compuesto de dehidropiridina.
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
TR200002207T1 (tr) Slekoksib bileşikleri.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
CO5640087A2 (es) Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
AR036877A1 (es) Formulacion farmaceutica
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160615